Merrick Pharmaceuticals, one of the largest pharmaceutical companies in the world, is working with Oracle to develop an implantable microchip that will allow the company to directly control the growth of drugs in a patient’s body.
Oracle’s Watson, a platform developed by Oracle Research Labs and the University of Illinois, will use artificial intelligence to make intelligent decisions about how to use a drug.
Merrick’s chip will enable drug discovery through a combination of machine learning and artificial intelligence, which means it will be able to identify and monitor the optimal dosage for a given drug, which could lead to a significant reduction in the cost of a drug by about 80% and a significantly improved safety profile.
Oracle is also developing a software suite called BioRobotics to provide software that will help doctors determine which drug is the right one for a patient.
The chip will be capable of reading the data it receives from its sensors and then using those signals to predict the optimal dose of a particular drug, according to a report published this week in Nature Communications.
Oracle is also collaborating with researchers at MIT, Harvard, the University at Buffalo and the Broad Institute to create a new system for using artificial intelligence and artificial biology to identify the optimal drugs to prescribe to a patient with an illness, according a company statement.
The system will use neural networks to analyze the patient’s data, analyze their medical history, and recommend the best drug to treat a given condition.
Researchers at the Broad, Harvard and MIT will develop the system.
“We’re thrilled to work with Merrick on our collaborative efforts to create an implant-based device that will be ideal for physicians, scientists and other healthcare professionals to use to treat patients with severe or life-threatening illnesses,” Dr. James R. Breen, vice president for healthcare innovation and product strategy at Merrick, said in a statement.
“We are excited to collaborate with Oracle on this exciting breakthrough,” Breen added.
More than 3,000 people died from a disease called COVID-19 this year, the most since the pandemic started in the United States in late 2014.
While it may seem like a relatively small amount of money, it could mean a huge boost to patients and their families who rely on Merrick for their care.
As of February 1, Merrick had about $1.4 billion in total sales, with a focus on clinical research and development.
According to Merrick’s financials, Oracle is expected to be the largest software company in the country with a $3.6 billion business.
However, the company’s stock has been in a steep decline, dropping more than 20% from its peak in June.
It’s unclear how much Oracle is making from this new chip, but the company has been able to make significant investments in artificial intelligence over the past few years.
In May, Merick invested in artificial intelligent startup Mindsight, which is now valued at more than $2.2 billion.
And in May, the firm said it had secured $50 million in Series B funding from Sequoia Capital, led by Google co-founder Sergey Brin.
If Oracle is able to successfully develop the chip, it will mark a significant milestone in artificial biology, said Dr. Andrew D. Miller, a medical doctor and professor at the Harvard Medical School who specializes in the medical applications of artificial intelligence.
Miller said it’s important that the chip is used in a way that is not only accurate, but that it is also cost effective, with the company hoping that the technology can also be used to develop new ways of controlling the growth or toxicity of drugs.
At this point, Miller said he is skeptical that Merrick will actually get to market with the implantable chip, given the company does not yet have a product.
But he said the company is very excited about the opportunity to develop this technology, and that the work will make a real difference to the way people in the healthcare industry treat and treat their patients.
“[Oracle] has a very important mission in this space,” Miller said.
“We are working to solve real problems that impact our healthcare, and we think this is a great opportunity to go in and help make a difference.”
The news comes at a time when the drug industry is in the midst of a shake-up.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has proposed that the federal government should consider lowering the approval threshold for new drugs, or phasing out the approval of new drugs for more than a year, to keep costs down and the potential to spur innovation.
PhRAA is also pushing for more funding for research and innovation, and has been pushing to create more jobs in the industry.
Meanwhile, the FDA has also recently been trying to crack down on drugs that have the potential for causing harm to patients.
The FDA announced last month